Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Integrated Transcriptomic and Proteomic Dynamics of Rituximab Treatment in Primary B Cells

ABSTRACT: The investigation aims to profile the molecular dynamics of Rituximab treatment in cells. Specifically, primary B cells were treated with Rituximab, and sampled across 6 time points. Treated and untreated cells were processed to extract RNA and protein, that were subsequently used in high-throughput analysis of the transcriptome (RNA-Sequencing) and proteome (mass spectrometry).

ORGANISM(S): Homo sapiens

PROVIDER: GSE100441 | GEO | 2018/10/13

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Integrated Transcriptomic and Proteomic Dynamics of Rituximab Treatment in B Lymphoblastoid Cells

Project description:The investigation aims to profile the molecular dynamics of Rituximab treatment in cells. Specifically, a B-lymphoblast cells line was treated with Rituximab, and sampled every hour over a 24hour period. Treated and untreated cells were processed to extract RNA and protein that were subsequently used in high-throughput analysis of the transcriptome (RNA-Sequencing) and proteome (mass spectrometry). We expect our approach not only to provide a unique reference dataset to the scientific community but to also act as a paradigm as an approach to identify novel transcriptome-proteome molecular markers utilized in mapping drug action pathways. We have identified specific expression at both the gene and protein levels and are inferring associations between the omics through the use of temporal pattern identification, thus defining time-varying networks. This study will provide the next steps in the development of reference dynamic omics data that may be used in creating integration models, with further applications in dynamic monitoring of samples in precision medicine implementation.

2017-09-15 | GSE89062 | GEO

Integrated Transcriptomic and Proteomic Dynamics of Everolimus Treatment in B Lymphoblastoid Cells

Project description:The investigation aims to profile the molecular dynamics of Everolimus treatment in cells. Specifically, a B-lymphoblast cells line was treated with Everolimus and sampled every half-hour over a 12 hour period. Treated and untreated cells were processed to extract RNA and protein that were subsequently used in high-throughput analysis of the transcriptome (RNA-Sequencing) and proteome (mass spectrometry).

2017-09-15 | GSE100359 | GEO

Integrated Transcriptomic and Proteomic Dynamics of Rituximab Treatment in B Lymphoblastoid Cells

Project description:The data describe the treatment of a human B cell lymphoblastoid cell line (B-LCL, line MS1). The cells were treated with Rituximab after 8 hours and the full untargeted proteomics and transcriptomics were profiled over a total of 24 hours, with samples acquired once every hour. A validation experiment was repeated as a separate experiment using a subset of the time points.

2016-10-13 | MSV000080244 | MassIVE

Antitumoral activity of acadesine and rituximab in MCL

2013-06-13 | GSE47871 | GEO

Antitumoral activity of acadesine and rituximab in MCL

Project description:Acadesine is a nucleoside analogue with known antileukemic effects in different neoplasms. We investigated the activity of acadesine ne exerts a cytotoxic effect in MCL and synergizes with rituximab supporting clinical examination of this strategy for MCL patients We used microarrays to detail the gene expression changes in acadesine-, rituximab- and combination-treated tumors. Global RNA expression in tumors treated with acadesine, rituximab and the combination in a xenograft model of MCL (Jeko-1). Tumors were collected 18 days after the initiation of the treatments.

2013-06-13 | E-GEOD-47871 | biostudies-arrayexpress

Prediction of survival in diffuse large B cell lymphoma treated with chemotherapy plus Rituximab

Project description:Gene expression profiling of DLBCL patient samples was performed to investigate, whether molecular gene expression signatures retain their prognostic significance in patients treated with chemotherapy plus Rituximab. The lymphnode, germinal center signature and a new angiogenesis signature were combined to a final multivariate model which defined quartile groups among Rituximab-CHOP-treated patients with distinct 3-year overall survival rates. Keywords: clinical history design

2008-11-28 | GSE10846 | GEO

Variation in gene expression patterns in follicular lymphoma and the response to rituximab

Project description:Abstract: Analysis of the patterns of gene expression in follicular lymphomas from 24 patients suggested that two groups of tumors might be distinguished. All patients, whose biopsies were obtained before any treatment, were treated with rituximab, a monoclonal antibody directed against the B cell antigen, CD20. Gene expression patterns in the tumors that subsequently failed to respond to rituximab appeared more similar to those of normal lymphoid tissues than to gene expression patterns of tumors from rituximab responders. These findings suggest the possibility that the response of follicular lymphoma to rituximab treatment may be predicted from the gene expression pattern of tumors. This SuperSeries is composed of the SubSeries listed below.

2006-03-07 | GSE4351 | GEO

Transcription profiling of human large B cell lymphoma treated with chemotherapy plus Rituximab to predict outcomes

2008-12-05 | E-GEOD-10846 | biostudies-arrayexpress

Genome-wide transcription analysis of whole blood prior to rituximab treatment in relation to clinical response

Project description:B cell depletion therapy is efficacious in RA patients failing on TNF blocking agents. However, approximately 40-50% of the rituximab-treated RA patients have a poor response. We investigated wheter baseline gene expression levels can discriminate between clinical nonresponders and responders to rituximab

2019-09-10 | GSE37107 | GEO

Genome-wide transcription analysis of whole blood prior to rituximab treatment in relation to clinical response

2012-04-09 | E-GEOD-37107 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data